A phenathiazide compound and its uses
By developing phenothiazine compounds to block voltage-gated Na+ channels on nerve cell membranes, the problems of short anesthetic time and poor efficacy of local anesthetic drugs in inflammatory environments have been solved, achieving rapid onset and long-lasting local anesthetic effects while avoiding the side effects of adrenaline.
Patent Information
- Application Number
- CN202311033423.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-16
- Filing Date
- 2023-08-16
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-08-16
AI Technical Summary
Existing local anesthetic drugs have problems such as short anesthesia time, poor efficacy in inflammatory environments, and side effects caused by combined use with adrenaline, which cannot meet the diverse needs of oral diagnosis and treatment procedures.
A phenothiazine compound was developed that provides rapid onset and prolonged local anesthesia even in inflammatory states by blocking voltage-gated Na+ channels on nerve cell membranes, while avoiding the side effects caused by adrenaline.
This compound significantly prolongs the duration of anesthetic effect after a single dose, and significantly prolongs the duration of local anesthesia in inflammatory states, overcoming the shortcomings of traditional local anesthetics and providing a safer and longer-lasting local anesthetic effect.
Smart Images

Figure CN117586223B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedicine, specifically relating to a phenthiazide compound and its uses. Background Technology
[0002] Local anesthetics are a class of drugs that reversibly block the generation and transmission of sensory nerve impulses at the site of application. In animals or humans with full consciousness, they reversibly block the generation and signal transmission of sensory nerve impulses locally, causing temporary loss of sensation in the affected area, thus reversibly inducing analgesia in the local tissue. Generally, the effect of local anesthetics is limited to the site of administration and disappears rapidly as the drug diffuses from the site. Local anesthetics produce their effect by directly inhibiting relevant ion channels on nerve cells and fiber membranes, blocking the generation of action potentials and the conduction of nerve impulses. The currently accepted mechanism of action of local anesthetics is the blocking of voltage-gated sodium channels on nerve cell membranes. + The channel blocks the conduction of nerve impulses, thereby producing a local anesthetic effect.
[0003] Currently used local anesthetics are all hydrophobic compounds without electrical charge, making them readily available to enter nerve cells through cell membranes via diffusion and osmosis, reaching the sodium channel blocking sites. These anesthetics block sodium channels, thereby inhibiting neuronal excitability. However, while these local anesthetic molecules easily diffuse into nerve cells to exert their effects, they also readily diffuse away from the administration site, becoming free within the nerve cells, resulting in a lack of sustained local anesthesia. Even increasing the dosage only extends the duration of local anesthesia to a certain extent; these drugs cannot achieve the desired long-term local anesthetic effect. Currently, the duration of action of most commonly used local anesthetics in clinical practice is no more than 4 hours. Due to the short duration of action of traditional local anesthetics, it is necessary to use analgesic pumps to maintain nerve blocks, requiring catheters placed in the spinal canal, nerve roots, or subcutaneously, significantly increasing medical costs and the incidence of infection.
[0004] Due to the nature of outpatient dental procedures, local anesthetics are widely used. Local anesthetics are generally used for minor outpatient surgeries such as tooth extractions, dental implants, root canal treatments, and subgingival scaling and root planing. Infiltration anesthesia and nerve block anesthesia are the most common methods. These characteristics require local anesthetics to have a rapid onset of action, moderate duration of action, and low toxicity. Therefore, intermediate-potency local anesthetics such as lidocaine, mepivacaine, prilocaine, and articaine are reasonable choices. Among them, articaine is currently the most widely used local anesthetic in dental treatment and is also the most potent amide anesthetic. Its structure is as follows:
[0005]
[0006] However, articaine also has some problems that urgently need to be addressed:
[0007] On the one hand, articaine, like nitric oxide, has a vasodilatory effect, promoting its systemic absorption, but its anesthetic duration is limited. Therefore, to prolong anesthesia time, reduce anesthetic dosage, minimize bleeding, and improve visualization of the surgical field, epinephrine is added to local anesthetics in clinical practice. However, the addition of epinephrine limits the use of articaine in specific patients such as children, women, those with cardiovascular disease, diabetes, or hyperthyroidism. Simultaneously, local vasoconstriction caused by epinephrine may lead to nerve and soft tissue ischemia, resulting in functional impairment. Although most literature acknowledges that epinephrine has a safe range, its concentration threshold remains unclear. Therefore, given the increasing number of patients with potential cardiovascular risks in an aging society, traditional local anesthetics cannot meet the needs of all oral procedures.
[0008] On the other hand, local anesthetics are less effective or ineffective in inflammatory environments. The oral and maxillofacial region is one of the most anatomically complex areas of the human body. Its rich blood supply, coupled with the long-term presence of various bacteria in the oral cavity and on the teeth, makes it prone to odontogenic inflammatory reactions, the most common being pericoronitis of the wisdom tooth. These inflammatory reactions can cause patients significant pain. However, clinically, it is often necessary to control the inflammatory reaction first, using pericoronal irrigation and antibiotics to eliminate the inflammation as quickly as possible. After the inflammation subsides, the causative tooth is extracted or treated otherwise. This is because local anesthetics cannot function properly in an inflammatory state. Furthermore, some patients with acute inflammatory conditions requiring emergency surgical intervention experience significant pain during and after the procedure. In such cases, if local anesthetics can provide stable relief, the pain caused by the treatment procedure can be greatly alleviated.
[0009] Therefore, it is of great significance to further study local anesthetics that are safe, have stable onset of action, short onset time, long duration of anesthesia, and can produce certain anti-inflammatory effects. Summary of the Invention
[0010] The purpose of this invention is to provide a novel compound for local anesthesia.
[0011] Compounds of Formula I, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated compounds thereof:
[0012]
[0013] Where R4 is C 1~8 hydrocarbon group, C 1~8 Alkoxy, 3- to 8-membered cyclic hydrocarbon group, phenyl or benzyl;
[0014] Where R1 is C 1~8 Hydrocarbon group, with R2 and R3 linked to form ring A:
[0015]
[0016] In ring A: R a R b R c R d R e R f R g R h C is selected independently from H, halogen, substituted or unsubstituted. 1~8 hydrocarbon group, C 1~8 Alkoxy or 3- to 8-membered cyclic hydrocarbon groups;
[0017] M is NR5, L is C 3~4 Alkane chain where R5 is H, or L is C. 1~4 Alkane chain with R5 being a substituted or unsubstituted C 1~8 hydrocarbon group, C 1~8 Alkoxy, 3-8 membered cyclic hydrocarbon group, phenyl or benzyl; the number of substituents is 1-3, and each substituent is independently selected from hydroxyl, halogen, amino, C 1~8 Alkoxy, 3- to 8-membered cyclic hydrocarbon groups or C 1~8 ester group; and ring A is When L is not a methylene chain; or, M is O, CH2, S, SO, or SO2, and L is C. 2~4 Branched alkane chains;
[0018] Or, R1 is C 1~8 Straight-chain alkyl group, and R2 is surrounded by 1 to 3 atoms. hydroxyl, amino, C 1~4 Alkoxy or C 1~4 alkylamino-substituted C 1~8 Alkyl group, R3 is hydrogen, unsubstituted or surrounded by 1 to 3 hydroxyl groups or C 1~4 alkoxy-substituted C 1~8 Alkyl; L is C 1~4 alkane chain;
[0019] Alternatively, R1 is isobutyl; R2 and R3 are independently selected from hydrogen, substituted or unsubstituted C atoms, respectively. 1~8 Hydrocarbon group, or substituted or unsubstituted C 1~8 The alkoxy group has 1 to 5 substituents, each of which is independently selected from hydroxyl or C. 1~4 Alkoxy group; L is C 1~4 Alkane chain.
[0020] Preferably, R4 is methyl.
[0021] Preferably, R1 is C 1~8 The alkyl group is connected with R2 and R3 to form a ring A; preferably, R1 is methyl and R2 and R3 are connected to form a ring A.
[0022] Preferably, in ring A: R a R b R c R d R e R f R g R h Each independently selected from H or C 1~8 Alkyl group, preferably H or methyl.
[0023] Preferably, M is NR5 and L is C. 3~4 Alkane chain where R5 is H, or L is C. 1~4 Alkane chain with R5 being a substituted or unsubstituted C 1~8 Alkyl, 3- to 8-membered cycloalkyl, or phenyl; the number of substituents is one or two, and each substituent is independently selected from hydroxyl, C... 1~4 Alkoxy or C 1~8 ester group; and ring A is In this case, L is not a methylene chain.
[0024] Preferably, M is NR5 and L is C. 1~4 Alkane chain with R5 being a substituted or unsubstituted C 1~4 Alkyl, cyclopropane, or phenyl; the number of substituents is one, and the substituent is hydroxy, methoxy, or methyl ester; and ring A is... In this case, L is not a methylene chain.
[0025] Preferably, the compound has the structure shown in Formula IA:
[0026]
[0027] Preferably, the compound has the structure shown in formula IA-1 or 1-A-2:
[0028]
[0029] Preferably, the compound has the structure shown in Formula IA-3:
[0030]
[0031] Among them, R5 is selected from C 1~4 alkyl.
[0032] Preferably, the compound has the structure shown in Formula IB:
[0033]
[0034] Preferably, the compound has the structure shown in formula IB-1, IB-2, IB-3 or IB-4:
[0035]
[0036]
[0037] Preferably, the compound has the structure shown in formula IC:
[0038]
[0039] Preferably, the compound has the structure shown in Formula IC-1:
[0040]
[0041] Preferably, the compound has the structure shown in Formula ID:
[0042]
[0043] Preferably, the compound has the structure shown in Formula ID-1:
[0044]
[0045]
[0046] Preferably, the compound has the structure shown in Formula IE:
[0047]
[0048] Preferably, the compound has the structure shown in Formula ID-1:
[0049]
[0050] Preferably, the compound has the structure shown in Formula IF:
[0051]
[0052] Preferably, the compound has the structure shown in Formula IF-1:
[0053]
[0054] Preferably, R1 is C 1~8 Straight-chain alkyl group, and R2 is separated by 1 hydroxyl, amino, C 1~4 Alkoxy or C 1~4 alkylamino-substituted C 1~3 Alkyl group, R3 is hydrogen, unsubstituted, or surrounded by one hydroxyl group or C. 1~4 alkoxy-substituted C 1~3 Alkyl; L is C 1~4 Alkane chain.
[0055] Preferably, L is
[0056] Preferably, R1 is isobutyl; R2 and R3 are each independently selected from hydrogen or C. 1~8 Alkyl; L is C 1~4 Alkane chain.
[0057] Preferably, L is
[0058] This invention also provides compounds of Formula II, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated compounds thereof:
[0059]
[0060] Where L` is C 1~4 alkane chain;
[0061] Where R5 is C 1~8 alkyl;
[0062] Where X` represents O, S, CH2, NR7, R7 is R i C substituted or unsubstituted 1~8 Alkyl, phenyl, or benzyl; R i It consists of hydroxyl groups, 3- to 8-membered ring hydrocarbon groups, and C. 1~8 Alkoxy or C 1~8 Ester group; R6 is C 1~8 Alkyl group; m and n are integers, and m+n = 2, 4, or 5;
[0063] Alternatively, when X is C, R6 is C. 1~8 Alkyl group; m and n are integers, and m+n=4 or 5;
[0064] k is selected from 0, 1, 2 or 3.
[0065] Preferably, L' is
[0066] Preferably, R5 is C 1~4 Alkyl group, R6 is C 1~4 Alkyl group, where X' is O, S, CH2, NR7, R7 is R i C substituted or unsubstituted 1~4 Alkyl or phenyl, R i It consists of hydroxyl groups, 3-6 membered ring hydrocarbon groups, and C. 1~4 Alkoxy or C 1~4 Ester group.
[0067] Preferably, R6 is a methyl group, and X is O, S, or C. NR7, R7 is R i C substituted or unsubstituted 1~4 Hydroxyl or phenyl, R i It can be hydroxyl, cyclopropyl, methoxy, or methyl ester group.
[0068] Preferably, the compound has the structure shown in any one of formulas II-A to II-F:
[0069]
[0070] Preferably, the compound has the structure shown in any one of formulas II-G to II-M:
[0071] Preferably, the compound has the structure shown in any one of formulas II-G to II-M:
[0072]
[0073]
[0074] Preferably, the compound has any of the following structures:
[0075]
[0076]
[0077]
[0078]
[0079]
[0080]
[0081]
[0082]
[0083] Preferably, the pharmaceutically acceptable salt refers to a salt formed by a compound of Formula I with a pharmaceutically acceptable inorganic or organic acid;
[0084] Preferably, the inorganic or organic acid is hydrochloric acid, hydrobromic acid, acetic acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, succinic acid, carbonic acid, tartaric acid, lauric acid, maleic acid, citric acid, or benzoic acid.
[0085] The present invention also provides the use of the above-mentioned compounds, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated compounds thereof, in the preparation of anesthetic drugs, preferably, the anesthetic drugs being local anesthetic drugs.
[0086] The present invention also provides the use of the above-mentioned compounds, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated compounds thereof, in the preparation of anti-inflammatory drugs.
[0087] The present invention also provides a drug preparation which is a formulation made of the above-mentioned compound, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a solvate thereof, or a prodrug thereof, or a metabolite thereof, or a deuterated compound thereof as the active ingredient, plus pharmaceutically acceptable excipients.
[0088] The beneficial effects of this invention are as follows: When used for local anesthesia, the compound of this invention has a rapid onset of action and a prolonged duration of anesthetic effect after a single dose. Compared with the 2-hour duration of local anesthesia of the local anesthetic articaine, the duration of local anesthesia of the compound of this invention can be significantly prolonged to 4 hours. At the same time, the compound of this invention can still exert a long-lasting local anesthetic effect in inflammatory states. Compared with the 0.5-hour duration of local anesthesia of the local anesthetic articaine in inflammatory states, the duration of local anesthesia of the compound of this invention in inflammatory states can be significantly prolonged to 1 hour.
[0089] The compounds of this invention exhibit prolonged local anesthetic effects in both infiltration and nerve block anesthesia, resolving the side effects associated with the combined use of local anesthetics and adrenaline, and thus demonstrating improved safety. These compounds can be used to prepare safe drugs with prolonged local anesthetic effects, offering advantages such as longer duration of local anesthesia, less nerve damage, and higher safety.
[0090] The "alkane chain" mentioned in this invention refers to an alkyl chain formed by removing two hydrogen atoms from a straight-chain or branched alkane.
[0091] "Alkyl" refers to a straight-chain or branched alkyl group, which is a group formed by removing one hydrogen atom from a straight-chain or branched alkane.
[0092] “C 1~8 "Ester group" refers to RCOO-, where R is C 1~8 Alkyl groups, specifically CH3COO-.
[0093] “C 1~4"alkylamino" refers to RNH-, where R is C 1~4 alkyl.
[0094] Obviously, based on the above description of the present invention, and according to common technical knowledge and conventional methods in the field, various other modifications, substitutions or alterations can be made without departing from the basic technical concept of the present invention.
[0095] The following detailed embodiments further illustrate the above-described content of the present invention. However, this should not be construed as limiting the scope of the present invention to the following examples. All technologies implemented based on the above-described content of the present invention fall within the scope of the present invention. Detailed Implementation
[0096] The raw materials and equipment used in this invention are all known products, obtained by purchasing commercially available products.
[0097] Example 1
[0098]
[0099] Step 1: Methyl 3-amino-4-methylthiophene-2-carboxylic acid (20.0 g, 116.8 mmol) was dissolved in 100 mL of DCM, and potassium carbonate (32.3 g, 233.6 mmol) was added. Then, 2-bromopropionyl bromide (32.8 g, 151.9 mmol) pre-dissolved in 20 mL of DCM was added at -20 °C, and the mixture was stirred at room temperature for 24 h. After the reaction was complete, the mixture was washed with water (100 mL × 3), and the organic phase was collected and dried over anhydrous sodium sulfate. After filtration, the solution was concentrated to 20 mL, and PE (200 mL) was added and stirred overnight. The product methyl 3-(2-bromopropamido)-4-methylthiophene-2-carboxylic acid (35.0 g, 97.8%) was obtained by filtration as a grayish-white solid.
[0100] 1 H NMR (400MHz, CDCl3) δ9.30 (s, 1H), 7.16 (s, 1H), 4.57 (q, J = 7.0Hz, 1H), 3.87 (s, 3H), 2.18 (s, 3H), 1.97 (d, J = 7.0Hz, 3H).
[0101] Step 2: 10.0 g (32.7 mmol) of methyl 3-(2-bromopropamido)-4-methylthiophene-2-carboxylic acid was dissolved in 30 mL of DMF. Potassium carbonate (3.86 g, 65.3 mmol) was added dropwise, followed by dropwise addition of propylamine (3.86 g, 65.3 mmol). The mixture was then stirred at room temperature for 5 h. After the reaction was complete, the mixture was diluted with 200 mL of DCM, washed with water (200 mL × 4), and the organic phase was collected and dried over anhydrous sodium sulfate. The mixture was filtered, dried, and concentrated. The residue was purified by column chromatography (DCM / MeOH = 50:1) to give methyl 4-methyl-3-(2-(propylamino)propamido)thiophene-2-carboxylic acid (8.66 g, 93.2%) as a pale yellow oil. This oil was dissolved in 80 mL of methanol, and 16 mL (2 M) of hydrochloric acid was added dropwise. The mixture was stirred at room temperature for 1 h, evaporated to dryness, dissolved in water, filtered, and the filtrate was lyophilized to obtain the hydrochloride salt of the product.
[0102] 1 H NMR(400MHz,D2O)δ7.36(s,1H),4.19(q,J=7.0Hz,1H),3.73(s,3H),2.97(ddt,J=40.5,1 2.2,7.6Hz,2H),2.05–1.91(m,3H),1.63(dd,J=12.0,7.2Hz,5H),0.89(t,J=7.4Hz,3H).
[0103] Step 3: Methyl 4-methyl-3-(2-(propylamino)propamido)thiophene-2-carboxylic acid (5.0 g, 17.6 mmol) was dissolved in 20 mL of MeOH, and sodium hydroxide (1.4 g, 35.2 mmol) pre-dissolved in 14 mL of water was added dropwise. The reaction mixture was then stirred at 50 °C for 2 h. After the reaction was complete, the mixture was concentrated under reduced pressure, and the residue was dissolved in 100 mL of water and washed with 100 mL of DCM. The aqueous phase was then adjusted to pH 7 with hydrochloric acid (2 M), and the aqueous phase was extracted with ethyl acetate. The organic phase was collected and dried over anhydrous sodium sulfate. The mixture was filtered, dried, and concentrated to obtain the crude product 4-methyl-3-(2-propylaminopropamido)thiophene-2-carboxylic acid (4.59 g, 96.6%).
[0104] 1 H NMR (400MHz, MeOD) δ7.02(s,1H),3.48(q,J=6.7Hz,1H),2.73–2.56(m,2H),2.12(s,3H),1.62–1.52(m,2H),1.46–1.39(m,3H),0.94(t,J=7.4Hz,3H).
[0105] HRMS(EI)m / z:calcd for C 12 H 19N2O3S,271.1111; found 271.1114[M+H] + .
[0106] HPLC purity: 95.393%, t R = 18.609 min.
[0107] Step 4: Dissolve 500 mg (1.85 mmol) of 4-methyl-3-(2-propylaminopropamido)thiophene-2-carboxylic acid in 20 mL of DMF, add sodium bicarbonate (311 mg, 3.70 mmol), and then add isobutyl chloride (340 mg, 3.7 mmol) dropwise at room temperature. React at 50 °C for 5 h. After the reaction is complete, dilute with 200 mL of DCM, wash four times with 100 mL of water, collect the organic phase, and dry it with anhydrous sodium sulfate. Filter, dry, and concentrate. Purify the residue by column chromatography (DCM / MeOH = 40:1) to obtain isobutyl 4-methyl-3-(2-(propylamino)propamido)thiophene-2-carboxylic acid (180 mg, 29.8%) as a colorless oil.
[0108] 1 H NMR (400MHz, D2O) δ7.48–7.34(m,1H),4.27(q,J=6.9Hz,1H),4.02(dd,J=6.3,2.2Hz,2H),3.05(ddt,J=27.5,12.1,7.8Hz,2 H),2.71(s,1H),2.06(s,3H),1.97(dt,J=12.1,6.5Hz,1H),1.81–1.64(m,5H),0.98(t,J=7.4Hz,3H),0.91(d,J=6.6Hz,6H).
[0109] 13 C NMR (101MHz, D2O) δ169.00,162.69,136.99,136.64,128.10,124.37,71.63,56.21,48.22,27.37,19.29,18.26,15.98,12.83,10.20.
[0110] HRMS(EI)m / z:calcd for C 16 H 17 N2O3S,327.1737; found 327.1739[M+H] + .
[0111] HPLC purity: 96.722%, t R = 17.558 min.
[0112] Example 2
[0113]
[0114] Methyl 3-(2-bromopropamido)-4-methylthiophene-2-carboxylic acid (1.5 g, 4.90 mmol) was dissolved in 20 mL of DMF, potassium carbonate (1.35 g, 9.80 mmol) was added, and ethylpiperazine (671 mg, 5.88 mmol) was added dropwise. The reaction was then carried out at 50 °C for 3 h. After the reaction was complete, the mixture was diluted with 200 mL of DCM, washed four times with 200 mL of water, and the organic phase was collected and dried over anhydrous sodium sulfate. The mixture was filtered, dried, and concentrated. The residue was purified by column chromatography (DCM / MeOH = 40:1) to give methyl 3-(2-(4-ethylpiperazin-1-yl)propamido)-4-methylthiophene-2-carboxylic acid (1.47 g, 88.4%) as a pale yellow oil. This oil was dissolved in 20 mL of methanol, and hydrochloric acid (5 mL, 2 M) was added dropwise. The mixture was stirred at room temperature for 1 h, evaporated to dryness, dissolved in water, filtered, and the filtrate was lyophilized to give the hydrochloride salt of the product.
[0115] 1 H NMR (400MHz, CDCl3) δ9.92(s,1H),7.13(d,J=0.9Hz,1H),3.84(s,3H),3.22(q,J=7.0Hz,1H),2.69(d,J= 40.6Hz, 8H), 2.47 (q, J = 7.2Hz, 2H), 2.16 (d, J = 0.9Hz, 3H), 1.35 (d, J = 7.0Hz, 3H), 1.12 (t, J = 7.2Hz, 3H).
[0116] 13 C NMR (151MHz, D2O) δ174.13,163.21,137.88,136.70,128.09,123.71,63.16,52.31,51.94,50.87,13.61,12.94,8.52.
[0117] HRMS(EI)m / z:calcd for C 16 H 26 N3O3S,340.1689; found 340.1685[M+H] + .
[0118] HPLC purity: 99.316%, t R = 15.207 min.
[0119] Example 3
[0120]
[0121] The reaction steps were the same as in Example 2, and the product was a colorless oil with a yield of 77.1%.
[0122] 1 H NMR(400MHz,D2O)δ7.38(s,1H),4.18(d,J=6.0Hz,1H),4.05–3.88(m,2H),3.74(s,3H),3.59(d,J=12.2Hz,1H),3.42(d,J=12 .1Hz,1H),2.93(t,J=11.6Hz,1H),2.82(t,J=11.7Hz,1H),1.99(s,3H),1.67(d,J=6.9Hz,3H),1.18(dd,J=14.0,6.3Hz,6H).
[0123] 13 C NMR (151MHz, D2O) δ168.18,163.02,136.54,136.52,128.32,124.49,69.52,64.51,55.06,52.85,52.41,17.40,17.28,13.68,12.68.
[0124] HRMS(EI)m / z:calcd for C 16 H 25 N2O4S,341.1530; found 341.1523[M+H] + .
[0125] HPLC purity: 98.351%, t R = 16.100min.
[0126] Example 4
[0127]
[0128] The reaction steps were the same as in Example 2, and the product was a colorless oil with a yield of 80.8%.
[0129] 1H NMR(400MHz,D2O)δ7.37(s,1H),4.11(q,J=6.9Hz,1H),3.74(s,3H),3.52(d,J=11.5Hz,1H),3.33(d,J=11.4Hz,1H),2.66(t,J=12.0Hz ,1H),2.52(t,J=12.0Hz,1H),1.99(s,3H),1.85(ddt,J=29.5,15.0,10.8Hz,3H),1.65(d,J=7.0Hz,3H),0.86(dt,J=15.5,7.8Hz,7H).
[0130] 13 C NMR(151MHz,D2O)δ168.75,163.06,136.69,136.59,128.34,124.47,64.1 7,57.70,55.18,52.44,38.27,29.04,28.70,17.65,17.58,13.80,12.74.
[0131] HRMS(EI)m / z:calcd for C 17 H 27 N2O3S,339.1737; found 339.1732[M+H] + .
[0132] HPLC purity: 96.029%, t R = 19.084 min.
[0133] Example 5
[0134]
[0135] The reaction steps were the same as in Example 2, and the product was a white oil with a yield of 21.0%.
[0136] 1 H NMR (400MHz, CDCl3) δ10.20(s,1H),7.12(s,1H),3.93–3.75(m,7H),3.43(dd,J=10.8,9.1Hz,1H),2.81(ddt,J=12 .2,9.1,4.5Hz,1H),2.63(tdd,J=11.4,7.9,4.1Hz,2H),2.17(s,3H),1.27(d,J=7.0Hz,3H),1.08(d,J=6.3Hz,3H).
[0137] 13C NMR (101MHz, CDCl3) δ172.50,162.81,142.20,136.06,127.13,117.76,73.36,67.36,58.11,52.22,51.77,46.64,15.75,14.23,8.67.
[0138] HRMS(EI)m / z:calcd for C 15 H 23 N2O4S,327.1373; found 327.1364[M+H] + .
[0139] HPLC purity: 95.906%, t R = 15.160 min and 16.403 min.
[0140] Example 6
[0141]
[0142] The reaction steps were the same as in Example 2, and the product was a colorless oil with a yield of 88.9%.
[0143] 1 H NMR (400MHz, CDCl3) δ10.07(s,1H),7.20–7.03(m,1H),3.84(s,3H),3.32(q,J=7.0Hz,1H),2.9 6(dt,J=12.7,7.2Hz,2H),2.85(d,J=6.4Hz,6H),2.17(d,J=0.9Hz,3H),1.32(d,J=7.0Hz,3H).
[0144] 13 C NMR (151MHz, D2O) δ168.22,163.00,136.61,136.56,128.32,124.45,64.02,52.42,24.19,13.44,12.71.
[0145] HRMS(EI)m / z:calcd for C 14 H 21 N2O3S2,329.0988; found 329.0980[M+H] + .
[0146] HPLC purity: 96.255%, t R = 16.582 min.
[0147] Example 7
[0148]
[0149] The reaction steps were the same as in Example 2, and the product was a pale yellow oil with a yield of 94.8%.
[0150] 1 H NMR (400MHz, CDCl3) δ10.06(s,1H),7.14(s,1H),3.84(s,3H),3.70(t,J=4.5Hz,4H),3.32( q,J=6.9Hz,1H),2.92–2.72(m,2H),2.69–2.37(m,6H),2.18(s,3H),1.44(d,J=6.9Hz,3H).
[0151] 13 C NMR (101MHz, CDCl3) δ173.85,162.91,141.94,136.14,127.25,118.39,67.02,59.18,58.09,53.71,53.47,51.83,44.94,20.09,15.53.
[0152] HRMS(EI)m / z:calcd for C 16 H 26 N3O4S,356.1639; found 356.1630[M+H] + .
[0153] HPLC purity: 99.524%, t R = 13.584 min.
[0154] Example 8
[0155]
[0156] The reaction steps were the same as in Example 2, and the product was a colorless oil with a yield of 61.7%.
[0157] 1H NMR (400MHz, CDCl3) δ10.05(s,1H),7.13(s,1H),4.19(dddd,J=10.3,8.6,6.2,2.4Hz,1H),3.83(d,J=1 .8Hz,3H),3.27(q,J=7.0Hz,1H),2.71(dt,J=10.9,2.0Hz,1H),2.57(dd,J=10.9,1.6Hz,1H),2.35(d,J =10.9Hz,1H),2.18(dd,J=3.0,0.8Hz,3H),1.93(q,J=11.1Hz,1H),1.46(s,2H),1.44(s,1H),1.36(s,1 H),1.34(s,1H),1.30(s,1H),1.29(d,J=2.6Hz,1H),1.23(d,J=3.6Hz,3H),1.12(dd,J=7.3,6.4Hz,3H).
[0158] 13 C NMR(101MHz,D2O)δ168.36,167.97,163.07,136.79,136.64,136.52,136.45,128.38,128.34,124.39,71.72,71.62 ,65.08,64.36,63.70,59.03,55.57,54.70,52.97,52.48,52.40,27.36,27.09,20.65,17.71,13.75,12.73,12.01.
[0159] HRMS(EI)m / z:calcd for C 17 H 27 N2O4S,355.1686; found 355.1680[M+H] + .
[0160] HPLC purity: 96.215%, t R = 19.348 min and 19.955 min.
[0161] Example 9
[0162]
[0163] The reaction steps were the same as in Example 2, and the product was a colorless solid with a yield of 17.6%.
[0164] 1H NMR(400MHz, CDCl3)δ9.99(s,1H),7.18–7.03(m,1H),3.82(s,3H),3.68(q,J=7.0Hz,1H),3 .60–3.49(m,4H),3.31(s,6H),2.91–2.71(m,4H),2.18–2.11(m,3H),1.32(d,J=7.0Hz,3H).
[0165] 13 C NMR (101MHz, CDCl3) δ172.82,162.49,141.58,136.23,126.73,126.64,119.42 ,71.76,61.58,61.49,58.84,51.80,51.68,50.80,15.35,15.29,10.17,10.11.
[0166] HRMS(EI)m / z:calcd for C 16 H 27 N2O5S,359.1635; found 359.1630[M+H] + .
[0167] HPLC purity: 95.108%, t R = 14.932 min.
[0168] Example 10
[0169]
[0170] The reaction steps were the same as in Example 2, and the product was a colorless oil with a yield of 35.3%.
[0171] 1 H NMR (400MHz, CDCl3) δ10.42(s,1H),7.07(d,J=1.1Hz,1H),3.78(s,3H),3.73–3.56(m,2H),3.51(q,J=7.0Hz,1H),3.47–3.29(m, 1H), 2.77(ddd,J=12.9,8.6,3.9Hz,1H),2.66–2.45(m,3H),2.16(d,J=1.0Hz,3H),1.25(d,J=7.0Hz,3H),1.07(t,J=7.1Hz,3H).
[0172] 13C NMR (101MHz, CDCl3) δ172.70,163.79,143.16,135.91,127.95,116.76,60.60,60.16,53.07,52.13,44.81,16.00,13.39,9.28.
[0173] HPLC purity: 95.438%, t R = 17.154 min.
[0174] Example 11
[0175]
[0176] The reaction steps were the same as in Example 2, and the product was a gray oil with a yield of 19.7%.
[0177] 1 H NMR (400MHz, CDCl3) δ10.24(s,1H),7.08(d,J=1.4Hz,1H),3.76(d,J=1.6Hz,3H),3.75–3.53(m,6H),3.49(qd,J=7.1,1.4Hz ,1H),2.76(ddt,J=12.4,10.0,3.1Hz,2H),2.60(dq,J=13.5,2.4Hz,2H),2.12(t,J=1.1Hz,3H),1.29(dd,J=7.1,1.8Hz,3H).
[0178] 13 C NMR (101MHz, CDCl3) δ172.21,163.91,142.75,136.47,128.00,118.01,60.95,60.17,52.54,52.24,15.57,9.40.
[0179] HPLC purity: 99.487%, t R = 16.202 min.
[0180] Example 12
[0181]
[0182] The reaction steps were the same as in Example 2, and the product was light butter with a yield of 52.3%.
[0183] 1H NMR (400MHz, CDCl3) δ9.82(d,J=18.2Hz,1H),7.05(d,J=1.0Hz,1H),3.76(s,3H),3.12(dq,J=17.8,7.0Hz,1H),2.86–2. 68(m,3H),2.60–2.35(m,2H),2.26(s,3H),2.21–1.97(m,5H),1.27(dd,J=7.0,2.5Hz,3H),1.01(dd,J=8.7,6.2Hz,3H).
[0184] 13 C NMR (101MHz, CDCl3) δ172.61,172.45,162.74,141.86,141.80,136.25,127.00,118.52,118.43,64.75,6 4.68,59.98,58.02,57.93,55.85,54.83,52.68,51.74,47.88,42.45,42.41,15.54,15.48,12.72,12.10.
[0185] HPLC purity: 99.293%, t R = 18.441 min.
[0186] Example 13
[0187]
[0188] The reaction steps were the same as in Example 2, and the product was light butter with a yield of 31.9%.
[0189] 1 H NMR (400MHz, CDCl3) δ10.05 (s, 1H), 7.08 (d, J = 1.2Hz, 1H), 3.76 (s, 3H), 3.4 6(q,J=7.0Hz,1H),3.37–2.91(m,8H),2.16–2.07(m,3H),1.57–1.26(m,3H).
[0190] 13 C NMR (101MHz, CDCl3) δ170.48,163.40,142.22,135.87,127.76,117.27,64.49,52.02,51.67,48.49,15.82,10.85.
[0191] HPLC purity: 98.852%, t R = 20.326 min.
[0192] Example 14
[0193]
[0194] Step 1: 2.0 g (6.53 mmol) of methyl 3-(2-bromopropamido)-4-methylthiophene-2-carboxylate was dissolved in a mixed solvent of 15 mL DMF and 15 mL ACN. Potassium carbonate (1.81 g, 13.06 mmol) and piperazine-1-carboxylate tert-butyl ester (1.46 g, 7.84 mmol) were added. The mixture was stirred at room temperature for 9 h. After the reaction was complete, the mixture was concentrated under vacuum. The residue was dissolved in 100 mL DCM and washed four times with 100 mL water. The organic phase was collected and dried over anhydrous sodium sulfate. The mixture was filtered, dried, and concentrated. The residue was purified by column chromatography (DCM / MeOH = 50:1) to give 2.68 g (99.7%) of 4-(1-((2-(methoxycarbonyl)-4-methylthiophene-3-yl)amino)-1-oxopropyl-2-yl)piperazine-1-carboxylate tert-butyl ester as a colorless oil.
[0195] 1 H NMR(400MHz, CDCl3)δ9.96(s,1H),7.05(d,J=1.1Hz,1H),3.76(s,3H),3.52(tt,J=13.1,7.0Hz,4H), 3.17(q,J=7.0Hz,1H),2.65–2.39(m,4H),2.10(d,J=1.0Hz,3H),1.41(s,9H),1.27(d,J=7.0Hz,3H).
[0196] Step 2: Dissolve 2.68 g (6.51 mmol) of 4-(1-((2-(methoxycarbonyl)-4-methylthiophen-3-yl)amino)-1-oxopropyl-2-yl)piperazine-1-carboxylic acid tert-butyl ester in 10 mL of dioxane, add dioxane hydrochloride solution (4 M; 4 mL, 16 mmol) dropwise, react at room temperature for 5 h, and filter. Wash the filter cake with dioxane to obtain methyl 4-methyl-3-(2-(piperazine-1-yl)propamido)thiophene-2-carboxylic acid (2.0 g, 79.8%) as a white solid.
[0197] 1 H NMR(400MHz,D2O)δ7.39(dd,J=10.7,4.3Hz,1H),4.35(dq,J=8.9,6.5Hz,1H),3 .83–3.69(m,5H),3.68–3.56(m,6H),2.08–1.93(m,3H),1.71(d,J=7.0Hz,3H).
[0198] 13C NMR(101MHz,D2O)δ168.20,163.08,163.04,136.64,136.61,128.43,124.4 9,124.44,64.24,52.52,46.97,40.89,40.86,13.95,13.91,12.84,12.80.
[0199] HPLC purity: 99.543%, t R = 17.497 min.
[0200] Example 15
[0201]
[0202] Methyl 3-(2-bromopropamido)-4-methylthiophene-2-carboxylic acid (4.78 g, 15.6 mmol) was dissolved in 30 mL of DMF, and potassium carbonate (4.32 g, 31.2 mmol) and 1-isopropylpiperazine (2.4 g, 18.7 mmol) were added. The reaction mixture was then stirred at 50 °C for 3 h. After the reaction was complete, the mixture was concentrated under vacuum. The residue was dissolved in 100 mL of DCM and washed four times with 100 mL of water. The organic phase was collected, concentrated, dissolved in water, and the pH was adjusted to 2-3 by adding 2 M hydrochloric acid. The aqueous phase was washed with DCM, and then the pH of the aqueous phase was adjusted to 10-11 with 2 M sodium hydroxide solution. The aqueous phase was extracted with DCM. The organic phase was collected and dried over anhydrous sodium sulfate. After filtration, drying, and concentration, the product methyl 3-(2-(4-isopropylpiperazin-1-yl)propamido)-4-methylthiophene-2-carboxylic acid (5.4 g, 97.8%) was obtained as a colorless oil. The product was dissolved in 50 mL of methanol, 15 mL of 2 M hydrochloric acid was added dropwise, the mixture was stirred at room temperature for 1 h, evaporated to dryness, dissolved in water, filtered, and the filtrate was freeze-dried to obtain the hydrochloride salt of the product.
[0203] 1 H NMR (400MHz, CDCl3) δ9.94 (s, 1H), 7.20–7.02 (m, 1H), 3.84 (s, 3H), 3.21 (q, J = 7.0Hz, 1H), 2.7 0(dq,J=12.9,6.4Hz,9H),2.17(d,J=0.9Hz,3H),1.35(d,J=7.0Hz,3H),1.09(d,J=6.5Hz,6H).
[0204] 13 C NMR (151MHz, D2O) δ173.85,163.22,137.85,136.69,128.11,123.71,63.16,58.43,52.32,47.62,16.05,13.64,12.94.
[0205] HRMS(EI)m / z:calcd for C 17 H 28 N3O3S,354.1846; found 354.1840[M+H] + .
[0206] HPLC purity: 98.948%, t R = 15.932 min.
[0207] Example 16
[0208]
[0209] The reaction procedure was the same as in Example 15, and the product was a colorless solid with a yield of 61.7%.
[0210] 1 H NMR(400MHz, CDCl3)δ9.91(s,1H),7.21–7.04(m,1H),3.84(s,3H),3.22(q,J=7.0Hz,1H),2.66( d,J=51.4Hz,7H),2.40(d,J=8.6Hz,1H),2.33(s,3H),2.20–2.11(m,3H),1.35(d,J=7.0Hz,3H).
[0211] 13 C NMR (101MHz, CDCl3) δ172.54,162.72,141.78,136.20,127.10,127.02,118 .45,64.84,55.28,51.86,51.76,46.10,46.02,15.60,15.55,12.59,12.53.
[0212] HRMS(EI)m / z:calcd for C 15 H 24 N3O3S,326.1533; found 326.1526[M+H] + .
[0213] HPLC purity: 98.402%, t R = 14.715 min.
[0214] Example 17
[0215]
[0216] The reaction steps were the same as in Example 15, and the product was a white oil with a yield of 70.8%.
[0217] 1 H NMR (400MHz, CDCl3) δ9.91 (s, 1H), 7.10 (s, 1H), 3.81 (s, 3H), 3.17 (q, J = 7.0Hz, 1H) ,2.66(d,J=26.6Hz,8H),2.14(d,J=0.9Hz,3H),1.32(d,J=7.0Hz,3H),1.08(s,9H).
[0218] 13 C NMR (101MHz, CDCl3) δ172.76,162.70,141.80,136.19,127.11,127.04,118.49,64 .83,53.74,51.83,51.72,45.84,25.92,25.86,15.63,15.58,15.54,12.74,12.67.
[0219] HRMS(EI)m / z:calcd for C 18 H 30 N3O3S,368.2002; found 368.1995[M+H] + .
[0220] HPLC purity: 98.050%, t R = 15.109 min.
[0221] Example 18
[0222]
[0223] The reaction steps were the same as in Example 15, and the product was a colorless oil with a yield of 51.0%.
[0224] 1 H NMR(400MHz, CDCl3)δ10.02(s,1H),7.20–7.04(m,1H),3.93–3.79(m,7H),3.18( q,J=7.0Hz,1H),2.74–2.55(m,4H),2.17(d,J=0.9Hz,3H),1.36(d,J=7.0Hz,3H).
[0225] 13C NMR (101MHz, CDCl3) δ172.31,162.87,141.96,136.11,127.25,127.21,118.00,67.14,65.39,51.86,51.79,50.71,15.68,15.64,12.74,12.71.
[0226] HRMS(EI)m / z:calcd for C 14 H 21 N2O4S,313.1217; found 313.1210[M+H] + .
[0227] HPLC purity: 99.358%, t R = 16.611 min.
[0228] Example 19
[0229]
[0230] The reaction procedure was the same as in Example 15, and the product was a pale yellow solid with a yield of 74.0%.
[0231] 1 H NMR (400MHz, CDCl3) δ9.95(s,1H),7.04(d,J=1.2Hz,1H),3.77(s,3H),3.14(q,J=7.0Hz,1H),2.70–2.34(m ,4H),2.09(d,J=1.0Hz,3H),1.63(pd,J=7.8,7.1,3.2Hz,4H),1.41(p,J=6.0Hz,2H),1.24(d,J=7.0Hz,3H).
[0232] 13 C NMR (101MHz, CDCl3) δ172.95,162.71,141.79,136.20,126.94,118.55,65.39,51.78,51.42,26.24,24.25,15.57,11.71.
[0233] HPLC purity: 95.461%, t R = 17.941 min.
[0234] Example 20
[0235]
[0236] The reaction steps were the same as in Example 15, and the product was a gray solid with a yield of 60.2%.
[0237] 1 H NMR (400MHz, CDCl3) δ10.01(s,1H),7.33–7.27(m,2H),7.13(d,J=1.1Hz,1H),7.02–6.94(m,2H),6.88(tt,J=7.3,1.1Hz,1H ),3.82(s,3H),3.44–3.24(m,5H),2.82(dddd,J=36.3,10.8,6.8,3.8Hz,4H),2.19(d,J=1.0Hz,3H),1.40(d,J=7.0Hz,3H).
[0238] 13 C NMR(101MHz,Chloroform-d)δ172.39,162.78,151.33,141.89,136.16,129.1 6,127.14,119.76,118.26,116.16,65.02,51.85,50.25,49.36,15.63,12.67.
[0239] HPLC purity: 98.645%, t R =20.010min.
[0240] Example 21
[0241]
[0242] Methyl 3-(2-bromopropamido)-4-methylthiophene-2-carboxylate (1.22 g, 3.98 mmol) was dissolved in 20 mL of DMF, and potassium carbonate (3.30 g, 23.91 mmol) and 1-propylpiperazine (511 mg, 3.98 mmol) were added. The reaction mixture was stirred overnight at room temperature. After the reaction was complete, the mixture was filtered, and the filtrate was concentrated under vacuum. The residue was dissolved in 100 mL of DCM and washed four times with 100 mL of water. The organic phase was collected and dried over anhydrous sodium sulfate. The mixture was filtered, dried, and concentrated. The residue was purified by column chromatography (DCM / MeOH = 40:1) to give methyl 4-methyl-3-(2-(4-propylpiperazin-1-yl)propamido)thiophene-2-carboxylate (912 mg, 74.8%) as a colorless oil. The product was dissolved in 10 mL of methanol, 5 mL of 2 M hydrochloric acid was added dropwise, the mixture was stirred at room temperature for 1 h, evaporated to dryness, dissolved in water, filtered, and the filtrate was freeze-dried to obtain the hydrochloride salt of the product.
[0243] 1H NMR(400MHz, CDCl3)δ9.89(s,1H),7.10(d,J=1.4Hz,1H),3.82(d,J=1.1Hz,3H),3.27–3.12(m,1H),2.87–2.3 8(m,8H),2.38–2.28(m,2H),2.14(d,J=1.1Hz,3H),1.59–1.44(m,2H),1.38–1.28(m,3H),0.96–0.81(m,3H).
[0244] 13 C NMR (101MHz, CDCl3) δ172.58,162.71,141.79,136.21,127.02,118.49,64.87,60.67,53.41,51.78,20.07,15.55,12.53,11.99.
[0245] HPLC purity: 98.935%, t R = 18.446 min.
[0246] Example 22
[0247]
[0248] The reaction steps were the same as in Example 21, and the product was a colorless oil with a yield of 52.7%.
[0249] 1 H NMR(400MHz, CDCl3)δ9.84(s,1H),7.05(d,J=1.2Hz,1H),3.77(s,3H),3.14(q,J=7.0Hz,1H),2.90–2.36(m, 8H),2.36–2.28(m,2H),2.09(d,J=1.0Hz,3H),1.50–1.38(m,2H),1.33–1.21(m,5H),0.86(t,J=7.3Hz,3H).
[0250] 13 C NMR (101MHz, CDCl3) δ172.56,162.73,141.80,136.22,127.03,118.49,64.87,58.47,53.43,51.79,29.05,20.81,15.55,14.07,12.53.
[0251] HPLC purity: 99.409%, t R = 19.173 min.
[0252] Example 23
[0253]
[0254] The reaction steps were the same as in Example 21, and the product was a colorless oil with a yield of 58.1%.
[0255] 1 H NMR (400MHz, CDCl3) δ9.84 (s, 1H), 7.05 (s, 1H), 3.76 (s, 3H), 3.46 (t, J = 5.6Hz, 2H), 3.2 9(s,3H),3.14(q,J=7.0Hz,1H),2.78–2.41(m,10H),2.09(s,3H),1.27(d,J=7.0Hz,3H).
[0256] 13 C NMR (101MHz, CDCl3) δ172.56,162.71,141.79,136.20,127.02,118.47,70.17,64.85,58.91,57.88,53.78,51.77,15.54,12.50.
[0257] HPLC purity: 99.002%, t R = 18.203 min.
[0258] Example 24
[0259]
[0260] The reaction steps were the same as in Example 21, and the product was a colorless oil with a yield of 82.0%.
[0261] 1 H NMR(400MHz,Chloroform-d)δ9.91(s,1H),7.10(d,J=1.0Hz,1H),3.82(s,3H),3.21(q,J=7.0Hz,1H),2.70(dd,J=26.5,4.6Hz,8H),2.29(d, J=6.6Hz,2H),2.15(d,J=1.0Hz,3H),1.34(d,J=7.0Hz,3H),0.88(ddtd,J=11.4,7.9,6.5,4.8Hz,1H),0.59–0.44(m,2H),0.17–0.07(m,2H).
[0262] 13C NMR (101MHz, CDCl3) δ172.35,162.50,141.61,135.98,126.82,118.20,64.65,63.51,53.23,51.53,15.35,12.27,8.15,3.70.
[0263] HPLC purity: 99.556%, t R = 18.690 min.
[0264] Example 25
[0265]
[0266] The reaction steps were the same as in Example 21, and the product was a colorless oil with a yield of 40.9%.
[0267] 1 H NMR(400MHz,Chloroform-d)δ9.84(s,1H),7.05(d,J=1.0Hz,1H),3.76(s,3H),3.58(t,J=5.4H z,2H),3.15(q,J=7.0Hz,1H),2.74–2.49(m,10H),2.09(d,J=1.0Hz,3H),1.28(d,J=7.0Hz,3H).
[0268] 13 C NMR (101MHz, CDCl3) δ172.54,162.86,141.93,136.27,127.19,118.41,64.96,59.37,57.88,53.13,51.87,15.65,12.72.
[0269] HPLC purity: 99.721%, t R = 17.124 min.
[0270] Example 26
[0271]
[0272] Step 1: The reaction procedure is the same as Step 1 in Example 1. White solid, yield 88.8%.
[0273] 1 H NMR (400MHz, CDCl3) δ9.36 (s, 1H), 7.10 (s, 1H), 3.97 (s, 2H), 3.82 (s, 3H), 2.13 (d, J = 1.0Hz, 3H).
[0274] Step 2: Same as Example 2, the product is colorless oil, with a yield of 46.3%.
[0275] 1 H NMR (400MHz, CDCl3) δ9.85 (s, 1H), 7.06 (s, 1H), 3.77 (s, 3H), 3.12 (s, 2H), 2.64 (dt, J = 13.6, 4.6Hz, 9H), 2.12 (s, 3H), 1.02 (d, J = 6.5Hz, 6H).
[0276] 13 C NMR (101MHz, CDCl3) δ167.83,161.70,140.49,135.23,126.11,117.67,61.03,53.47,52.97,50.77,47.70,17.65,14.59.
[0277] HPLC purity: 97.830%, t R = 17.898 min.
[0278] Example 27
[0279]
[0280] Step 1: The reaction procedure is the same as Step 1 in Example 1. White solid, yield 87.0%.
[0281] 1 H NMR (400MHz, CDCl3) δ9.26 (s, 1H), 7.09 (d, J = 1.1Hz, 1H), 4.33 (dd, J = 7.8, 5.7Hz, 1H), 3.81 (s, 3H), 2.26–2.01 (m, 5H), 1.06 (t, J = 7.3Hz, 3H).
[0282] Step 2: Same as Example 2, the product is colorless oil, with a yield of 28.7%.
[0283] 1 H NMR (400MHz, CDCl3) δ9.75 (s, 1H), 7.05 (d, J = 1.5Hz, 1H), 3.77 (s, 3H), 2.89–2.84 (m, 1H), 2.6 3(ddt,J=25.6,19.5,8.7Hz,9H),2.13(d,J=1.4Hz,3H),1.85–1.67(m,2H),1.06–0.92(m,9H).
[0284] 13C NMR (101MHz, CDCl3) δ170.73,161.90,141.18,135.03,126.24,116.70,70.52,53.50,50.74,47.86,20.80,17.63,17.59,15.02,10.19.
[0285] HPLC purity: 99.081%, t R = 19.175 min.
[0286] Example 28
[0287]
[0288] The reaction steps were the same as in Example 1, and the product was a colorless oil with a yield of 36.3%.
[0289] 1 H NMR(400MHz,D2O)δ7.43(s,1H),4.27(q,J=7.0Hz,1H),4.21(t,J=6.5Hz,2H),3.15–2. 97(m,2H),2.83(s,1H),2.07(s,3H),1.80–1.65(m,7H),0.96(dt,J=22.1,7.4Hz,6H).
[0290] 13 C NMR (101MHz, D2O) δ169.06,162.85,136.86,136.64,128.20,128.16,124.55,67.53,56.21,48.20,21.52,19.29,15.93,12.81,10.18,9.63.
[0291] HRMS(EI)m / z:calcd for C 15 H 15 N2O3S,313.1580; found 313.1580[M+H] + .
[0292] HPLC purity: 97.343%, t R = 19.234 min.
[0293] Example 29
[0294]
[0295] The reaction steps were the same as in Example 1, and the product was a colorless oil with a yield of 43.1%.
[0296] 1 H NMR(400MHz,D2O)δ7.31(d,J=7.5Hz,1H),4.17(dt,J=13.6,6.7Hz,3H),3.06–2.84(m,2H),2.74(s,1H),1.97(d ,J=1.5Hz,3H),1.70–1.52(m,7H),1.28(qt,J=9.4,4.9Hz,2H),0.88(td,J=7.4,1.3Hz,3H),0.83–0.75(m,3H).
[0297] 13 C NMR (101MHz, D2O) δ168.99,162.78,137.05,136.65,128.07,124.46,65.80,56.21,48.21,30.05,19.30,18.62,15.96,12.99,12.83,10.20.
[0298] HRMS(EI)m / z:calcd for C 16 H 17 N2O3S,327.1737; found 327.1737[M+H] + .
[0299] HPLC purity: 98.835%, t R = 19.758 min.
[0300] Example 30
[0301]
[0302] The reaction steps were the same as in Example 1, and the product was a colorless oil with a yield of 50.7%.
[0303] 1 H NMR(400MHz,D2O)δ7.44(d,J=0.9Hz,1H),4.29(dq,J=10.5,7.1Hz,3H),3.15–2.97(m,2H), 2.83(s,1H),2.07(s,3H),1.84–1.63(m,5H),1.31(t,J=7.1Hz,3H),0.98(t,J=7.5Hz,3H).
[0304] 13C NMR (101MHz, D2O) δ169.10,162.81,136.84,136.64,128.19,124.62,62.23,56.19,48.18,19.28,15.87,13.52,12.80,10.17.
[0305] HRMS(EI)m / z:calcd for C 14 H 23 N2O3S,299.1424; found 299.1427[M+H] + .
[0306] Example 31
[0307]
[0308] The reaction steps were the same as in Example 1, and the product was a colorless oil with a yield of 31.5%.
[0309] 1H NMR(400MHz,Chloroform-d)δ6.97(s,1H),4.24(t,J=6.1Hz,1H),3.84–3.75(m,1H),2.79(qd,J=5.0,3.1Hz,1H),1.83 –1.73(m,1H),1.57–1.46(m,1H),1.44–1.36(m,1H),1.40–1.30(m,1H),1.33–1.24(m,5H),0.90(dt,J=8.6,6.9Hz,3H).
[0310] HRMS(EI)m / z:calcd for C 20 H 34 N2O3S,299.1424; found 383.2369[M+H] + .
[0311] Example 32
[0312]
[0313] The reaction steps were the same as in Example 2, and the product was a colorless oil with a yield of 71.5%.
[0314] 1H NMR(400MHz,Chloroform-d)δ9.47(s,1H),6.98(s,1H),3.91(s,3H),3.57(q,J=6.4Hz,1H),2.86–2.69(m,3H ),2.25(d,J=0.7Hz,3H),1.74–1.47(m,4H),1.39–1.26(m,4H),1.11(d,J=5.9Hz,3H),0.92(d,J=6.4Hz,3H).
[0315] HRMS(EI)m / z:calcd for C 17 H 26 N2O3S,339.1737; found 339.1670[M+H] + .
[0316] Example 33
[0317]
[0318] The reaction procedure was the same as in Example 2. Methyl 3-(2-(4-ethylpiperazin-1-yl)propamido)-4-methylthiophene-2-carboxylic acid was dissolved in methanol, hydrochloric acid solution was added dropwise at room temperature, and the mixture was stirred at room temperature for 1 hour before being evaporated to dryness. The residue was dissolved in water and filtered to remove impurities. The filtrate was freeze-dried to obtain the hydrochloride salt of the product.
[0319]
[0320]
[0321]
[0322]
[0323]
[0324]
[0325]
[0326] The reaction conditions for the preparation of the above compounds are the same as those in Example 1, except that the corresponding raw materials are replaced according to the differences in the substituents.
[0327] Example 106
[0328]
[0329] 1a (20.0 g, 116.80 mmol) was dissolved in 100 mL of dichloromethane (DCM), and 23.6 g of triethylamine was added. 2-Bromopropionyl bromide (27.7 g, 128.5 mmol) dissolved in 20 mL of DCM was added dropwise at 0 °C. The mixture was stirred at room temperature for 12 h, and the reaction was monitored by TLC. When the reaction was nearly complete, it was extracted with DCM, and the organic phase was dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated under reduced pressure to obtain 33.2 g of off-white solid powder 1c, with a yield of 93%.
[0330] 1 H NMR (500MHz, Chloroform-d) δ9.30 (s, 1H), 7.16 (s, 1H), 4.57 (q, J = 7.0Hz, 1H), 3.87 (s, 3H), 2.18 (s, 3H), 1.97 (d, J = 7.0Hz, 3H).
[0331] Compound 1c (3.0 g, 9.80 mmol) and potassium carbonate (2.7 g, 19.60 mmol) were added to 30 mL of DMF, and 1d (1.08 g, 10.78 mmol) was added with stirring. The mixture was stirred at 50 °C for 2 h. The reaction solution was evaporated to dryness under reduced pressure. The crude product was purified by silica gel column chromatography with DCM:MeOH = 50:1 as the eluent. 2.8 g of colorless oil 1 was obtained after purification. Yield: 88%.
[0332] 1 H NMR(500MHz,Chloroform-d)δ9.43(s,1H),6.98(s,1H),3.91(s,2H),3.78(d,J=0.9Hz,1H),3.65(d,J=0.9Hz,1H),3.45(q,J=6.8Hz,1H) ,2.97(ddd,J=12.3,4.4,1.9Hz,1H),2.66–2.55(m,4H),2.50(ddd,J=11.4,4.4,1.9Hz,1H),1.32(d,J=6.6Hz,3H),1.07(t,J=7.2Hz,3H).
[0333] Example 107
[0334]
[0335] Compound 1c (2.0 g, 6.53 mmol) and potassium carbonate (1.8 g, 13.06 mmol) were added to 20 mL of DMF. Compound 2b (1.08 g, 10.78 mmol) was added with stirring. The mixture was stirred at 50 °C for 2 h. The reaction solution was evaporated to dryness under reduced pressure. The crude product was purified by silica gel column chromatography with an eluent of DCM:MeOH = 50:1. 1.8 g of a colorless oily substance, 2c, was obtained after purification. The yield was 81%.
[0336] 1 H NMR(500MHz,Chloroform-d)δ9.43(s,1H),6.98(s,1H),3.91(s,2H),3.73(t,J=0.7Hz,1H),3.66(d,J=0.8Hz,1H),3.46(q,J=6.7Hz,1H),3.02(ddd,J=1 2.3,4.6,2.7Hz,1H),2.99–2.87(m,2H),2.79(dddd,J=25.4,12.2,4.4,2.6 Hz,2H),1.32(d,J=6.8Hz,3H),1.15(d,J=6.8Hz,3H),1.10(d,J=6.6Hz,3H).
[0337] 2c (1.0 g, 2.95 mmol) was dissolved in 20 mL of MeOH, sodium hydroxide solution was added, and the mixture was stirred at 50 °C for 2 h. The reaction was monitored by TLC until complete. After filtration, the solvent was evaporated to dryness under reduced pressure. The solid was dissolved in 50 mL of water and extracted with n-butanol (50 mL × 5). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 800 mg of white solid. The solid was dissolved in 20 mL of DMF, and bromoethane (495 mg, 5.89 mmol) was added. The mixture was reacted at room temperature for 5 h. The reaction was monitored by TLC until complete. 100 mL of DCM was added, and the mixture was washed three times with 200 mL of water. The organic phase was dried over anhydrous sodium sulfate and the solvent was evaporated to dryness under reduced pressure. Column chromatography purification gave 750 mg of colorless oil 2, with a yield of 72%.
[0338] 1H NMR(500MHz,Chloroform-d)δ9.42(s,1H),6.98(s,1H),4.32(q,J=6.4Hz,2H),3.73 (t,J=0.7Hz,1H),3.66(d,J=0.7Hz,1H),3.46(q,J=6.7Hz,1H),3.02(ddd,J=12.3,4 .6,2.7Hz,1H),2.99–2.87(m,2H),2.79(dddd,J=25.4,12.2,4.3,2.6Hz,2H),1.36( t,J=6.4Hz,3H),1.32(d,J=6.8Hz,3H),1.15(d,J=6.8Hz,3H),1.10(d,J=6.6Hz,3H).
[0339] Example 108
[0340]
[0341] 600 mg of the product from Example 70 was dissolved in 10 mL of methanol, and twice the amount of the substance of a 0.1 mol / L hydrochloric acid-methanol solution was added dropwise under ice bath, followed by concentration under reduced pressure. The residue was dissolved in water and filtered, and the filtrate was freeze-dried under vacuum to obtain a white solid 3.
[0342] Example 109
[0343]
[0344] Starting material 4a (3.0 g, 14.98 mmol) was dissolved in 30 mL of ACN, and potassium carbonate (4.14 g, 29.96 mmol) and 1-bromobutane (2.26 g, 16.48 mmol) were added. The mixture was stirred overnight at room temperature, and the reaction was monitored by TLC until complete. The mixture was filtered, and the ACN was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (EA:PE = 20%) to give 2.0 g of a colorless oil, with a yield of 85%.
[0345] 1 H NMR(500MHz,Chloroform-d)δ2.84–2.70(m,4H),2.62(dt,J=6.0,5.2Hz,2H),2.50(dt,J=11.2,6.3Hz,2H),2.44(t ,J=6.5Hz,2H),2.15–2.08(m,1H),1.76–1.66(m,2H),1.51–1.42(m,2H),1.37–1.27(m,2H),0.93(t,J=7.4Hz,3H).
[0346] The compound was dissolved in 10 mL of DCM, and 10 mL of TFA was added. The mixture was stirred at room temperature for 1 h, and the reaction was completed by TLC. The solvent was then evaporated to dryness to give compound 4c. Compound 1c (3.56 g, 11.63 mmol) and potassium carbonate (6.43 g, 46.54 mmol) were added to 30 mL of DMF, and compound 4c (12.80 mmol) was added while stirring. The mixture was stirred at room temperature for 5 h, and the reaction solution was evaporated to dryness under reduced pressure. The crude product was purified by silica gel column chromatography with an eluent of DCM:MeOH = 50:1. After purification, 3.6 g of colorless oily substance 4 was obtained. The yield was 81%.
[0347] Example 110
[0348]
[0349] 1.0 g of the product from Example 109 was dissolved in 15 mL of methanol, and an equal amount of 0.1 mol / L sulfuric acid-methanol solution was added dropwise under ice bath. The solution was then concentrated to dryness under reduced pressure. The residue was dissolved in water and filtered. The filtrate was freeze-dried under vacuum to obtain a white solid (5).
[0350] Following the methods described in the above embodiments, the following compounds were obtained:
[0351]
[0352]
[0353]
[0354]
[0355] The reaction conditions for the preparation of the above compounds are the same as those in Example 107, except that the corresponding raw materials are replaced according to the differences in the substituents.
[0356] The following experimental examples demonstrate the beneficial effects of the present invention. In the following experiments, the compounds prepared in each example are named according to the example number; for example, the compound prepared in Example 1 is named Compound 1.
[0357] Experimental Example 1: Local anesthetic effect of the compound of the present invention
[0358] 1. Sciatic nerve block model
[0359] Compounds prepared in Examples 1-168 (compounds 1-168) were selected. Eight groups of test rats, each with 6 rats, were given the articaine positive control group and were fully adapted to the experimental environment.
[0360] The dosage was as follows: the concentration of articaine in the group was 2% aqueous solution, and the concentration of the test drug was 62 mmol / L physiological saline solution.
[0361] The injection volume for each rat (drug administration or control) was 0.5 ml, injected near the sciatic nerve using a nerve locator. The local anesthetic effect was observed by stimulating the plantar surface of the rat's paw on the side where the drug was injected using a von Frey stimulator. Simultaneously, the rat's motor function was evaluated using the Postural Extensor Thrust (PET) test: the rat was lifted vertically and its injected hind limb was placed on an electronic balance platform. The hind limb muscle strength at this point was represented by the value displayed on the balance. In cases of complete limb paralysis, the reading was the limb's own weight, approximately 20 g. A measurement exceeding half the difference between baseline and limb weight was considered a recovery of motor function; a value less than or equal to this value was considered a loss of motor function.
[0362] Table 1. Local sciatic nerve anesthetic effect of the compounds of the present invention.
[0363]
[0364]
[0365]
[0366]
[0367]
[0368]
[0369] Experimental results show that this type of drug can produce a stronger anesthetic effect than articaine. At the same dosage, this type of drug can produce a local anesthetic sensory blockade time of more than 2 hours in the sciatic nerve block model.
[0370] 2. Rat subcutaneous infiltration model
[0371] After shaving and disinfecting the backs of rats weighing 250–300 grams, a circle approximately 1.5 cm in diameter was drawn on one side of the bare back, and the circle was divided into 6 equal parts. 0.5 mL of a drug-containing solution (using physiological saline as a solvent, 2% articaine (62 mmol / L, the concentration range of the compound described in this patent is 62 mmol / L) was injected subcutaneously into the center of the circle. A 100-gram fiber from a Von Frey fiber was attached to the needle for local skin stimulation. One minute after injection, stimulation was performed in each of the 6 divided areas using the same method. If no skin contraction was observed in three consecutive stimulations within the same area, the drug effect was considered positive; if skin contraction occurred, the local anesthetic effect was considered lost. If four or more areas in the 6 divided areas showed positive local anesthesia, the local anesthesia was considered effective; if fewer than four areas showed positive local anesthesia, the local anesthesia was considered ineffective. Six rats were used for each compound in the experiment.
[0372] Table 2. Subcutaneous infiltration local anesthetic effect of the compounds of this invention.
[0373]
[0374]
[0375]
[0376]
[0377]
[0378]
[0379] Experimental results show that, at the same dosage, this type of drug, compared with articaine, can produce a local anesthetic effect of more than 3 hours in a rat subcutaneous infiltration model.
[0380] Experimental Example 2: Safety of the Compounds of the Present Invention
[0381] 1. Mouse LD 50 value
[0382] Mice weighing 18.0g-21.0g were randomly selected for tail vein LD50 testing. 50Measurements were performed using a sequential method. The mouse tail was gently wiped with a 75% alcohol swab to soften the tail keratin layer and dilate the tail vein. Different concentrations of drug were then injected into the tail vein using a syringe. The administration rate was 10-15 seconds, and the total injection volume did not exceed 1.0 mL. Based on the preliminary experimental results, three additional doses were set up in a geometric progression between the highest dose (i.e., the minimum lethal dose) and the lowest dose (i.e., the maximum non-lethal dose), for a total of five dose groups. The optimal dose ratio between groups was 1:0.6 to 1:0.85. Administration began with the intermediate dose, and mouse mortality was observed. If a mouse did not die, the next mouse was given a higher dose; if a mouse died, the next mouse was given a lower dose, and so on, until six crossovers occurred in the same direction, at which point the experiment ended.
[0383] The sequential method is used to calculate the formula LD. 50 =lg -1 [X0+i(A / N)±0.5] calculates the LD50 of the drug. 50 .
[0384] The central group d (group interval) is set to 0, and the values are 1 and 2 as the dose increases, and -1 and -2 as the dose decreases; X0 represents the logarithmic dose when d = 0; i (logarithmic dose group interval) represents the logarithm of the common ratio reciprocal; a is the number of positives at the corresponding dose; N and A represent the sum of a and ad, respectively.
[0385] Table 3. Mouse tail vein LD50 of the compounds of the present invention 50 Value measurement results
[0386]
[0387] Experimental results show that the LD50 of this type of drug in mice is... 50 The value is higher than that of the positive drug articaine, indicating that this type of compound has a higher safety profile than articaine.
[0388] 2. Neuropathological injury assessment
[0389] The drugs from Examples 1 to 168 were selected. The articaine positive control group was given to 8 rats that were fully adapted to the experimental environment.
[0390] The dosage was: 2% articaine aqueous solution, and the test drug concentration was 62 mmol / L aqueous solution. The injection volume for each rat (administered or controlled) was 0.5 mL, injected near the sciatic nerve. On days 7 and 14 after the sciatic nerve injection, the experimental rats were euthanized by cardiac injection of bupivacaine under isoflurane anesthesia. Approximately 1.5 cm of the sciatic nerve at the injection site was harvested, stored in 10% formaldehyde solution for 48 h, stained with hematoxylin and eosin (HE), and sectioned into 5 μm thick sections.
[0391] Neuropathological damage assessment showed that, compared with the articaine positive control group, the drugs in Examples 1-168 did not show significant differences in nerve damage, angiogenesis, degree of demyelination, muscle inflammation, and degree of connective tissue inflammation, and had good safety.
[0392] Experimental Example 3: The compound of the present invention can still exert its effects under inflammatory conditions and has anti-inflammatory properties.
[0393] 1. CFA-induced plantar inflammation model
[0394] The drugs from Examples 1 to 168 were selected. The articaine positive control group was given to 8 rats that were fully adapted to the experimental environment. After injecting CFA (complete Freund's adjuvant) into the right paw of each rat for 48 hours, obvious paw swelling was observed and the claw retraction threshold of the right hind paw was significantly reduced as measured by the Von Frey stimulator. At this time, subcutaneous administration of the drug to the paw was possible.
[0395] The dosage was: 2% articaine aqueous solution, and the test drug concentration was 62 mmol / L aqueous solution. The injection volume for each rat (administered or controlled) was 0.2 mL, injected subcutaneously into the swollen area of the rat's paw. The local anesthetic effect was observed by stimulating the paw on the side of the rat injected with the drug using a von Frey stimulator. Tests were performed every 10 minutes after the onset of action. A measurement exceeding half the difference between the limb weight and baseline was considered anesthesia effective; a value less than or equal to this value was considered anesthesia ineffective.
[0396] Table 4 shows the effects of the compounds of this invention in a CFA-induced plantar inflammation model.
[0397]
[0398]
[0399]
[0400]
[0401]
[0402]
[0403] Experimental results show that, at the same dosage, this type of drug, compared with articaine, can produce a local anesthetic effect of at least more than 1 hour in the CFA-induced plantar inflammation model.
[0404] 2. LPS inflammation model at the cellular and molecular level
[0405] 1*10^5 cells (primary DRG cells) were seeded in 6-well plates. After 24 hours of adhesion, the cells were divided into three groups: Group 1 was treated with complete culture medium for 48 hours; Group 2 was treated with 1 μg / ml LPS for 24 hours, followed by 24 hours of treatment with complete culture medium; and Group 3 was treated with 1 μg / ml LPS for 24 hours, followed by 24 hours of treatment with complete culture medium containing 1 mM of the compound of this invention. RNA was extracted from each group of cells, reverse transcribed into cDNA, and the expression changes of inflammatory factors (IL1β, IL6, TNFα) in each group were detected by RT-qPCR.
[0406] Compound 15 prepared in Example 15:
[0407]
[0408] Compound 16 prepared in Example 16:
[0409]
[0410] Compound 22 prepared in Example 22:
[0411]
[0412]
[0413] Experimental results showed that this class of drugs could significantly reduce the levels of LPS-induced cellular inflammatory factors (IL1β, IL6, TNFα), and the differences were statistically significant (P<0.05).
[0414] In summary, the compounds of this invention have a rapid onset of action and a prolonged duration of anesthetic effect after a single dose when used for local anesthesia. They exhibit a long-lasting local anesthetic effect in both infiltration and nerve block anesthesia, solving the side effects problem associated with the combined use of local anesthetics and adrenaline, and thus demonstrating better safety. The compounds of this invention can be used to prepare safe drugs with prolonged local anesthetic effects, offering advantages such as long duration of local anesthetic action, less nerve damage, high safety, and anti-inflammatory effects.
Claims
1. The compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the structure of the compound of Formula I is shown in Formula IA-3: in, R5 is selected from C 1~4 alkyl.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, characterized in that, The compound has any of the following structures: 、 、 。 3. The compound as claimed in claim 1 or 2, or a pharmaceutically acceptable salt thereof, characterized in that, The pharmaceutically acceptable salt is formed by the compound and a pharmaceutically acceptable inorganic or organic acid.
4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, characterized in that, The inorganic or organic acid is hydrochloric acid, hydrobromic acid, acetic acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, succinic acid, carbonic acid, tartaric acid, lauric acid, maleic acid, citric acid, or benzoic acid.
5. Use of the compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, in the preparation of an anti-inflammatory drug.
6. A drug, characterized in that, It is a formulation prepared by using the compound described in any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, as the active ingredient, plus pharmaceutically acceptable excipients.
Citation Information
Patent Citations
3-aminoacylamino-thiophens and process for preparing them
GB1234833A
